The FDA has received adverse event reports from people using compounded semaglutide, which might not contain the same version of the popular obesity drug.
Semaglutide is a synthetic and longer-lasting version of glucagon-like peptide 1 developed by the company Novo Nordisk. GLP-1 and similar hormones help regulate our hunger and metabolism, often by affecting the release of other hormones such as insulin. As a result, GLP-1-basedhave been used for over a decade to help people manage their type 2 diabetes.
demand soon led to shortages of the drug. This demand has also led to shortages of Ozempic, the lower-dose brand of semaglutide approved for diabetes, as doctors began to prescribe it off-label for weight loss. Novo Nordisk has predictably disavowed the use of compounded semaglutide, stating that they do not sell the active ingredient to these pharmacies. On Tuesday, the FDA issued its own
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
CEOs see ChatGPT, generative AI as 'Ozempic' style cure-allCEOs see ChatGPT as an 'Ozempic' miracle drug that can cut costs and boost efficiency. Right now, they're wrong.
Weiterlesen »
Ozempic: Weight loss, side effects and potential to treat addictionThe drugs Ozempic and Wegovy can help people who are obese or overweight to quickly lose weight, but some are concerned they may cause hair loss or a gaunt appearance, dubbed 'Ozempic face'. What's the science behind the treatments?
Weiterlesen »
FDA issues warning about some compounded versions of semaglutide for diabetes, weight loss | CNNThe US Food and Drug Administration issued a warning Tuesday about compounded versions of the drug semaglutide, which is approved for treatment of diabetes and excess weight.
Weiterlesen »
When courts challenge the FDA’s authority, they put patients’ lives at riskThe entire biotechnology and pharmaceutical industry will be thrown into turmoil if judges can second-guess the scientific expertise of the US Food and Drug Administration.
Weiterlesen »
‘Exciting Time’: FDA Commissioner Talks AI and MisinformationShould we be worried about AI's growing influence in healthcare, and what can the FDA do about the Adderall shortage? WebMD Chief Medical Officer drjohnwhyte sat down with US_FDA Commissioner Dr. Robert M. Califf to talk about this and more. Watch here:
Weiterlesen »
FDA warns about compounded versions of popular weight loss drugsFederal health officials say some medications being sold may not contain the same active ingredient as FDA-approved semaglutide products.
Weiterlesen »